Therefore, in China, ZOL-FO is unlikely to be a cost-effective first-line treatment strategy for CLDN18.2-positive, HER2-negative advanced G/GEJ adenocarcinoma compared with PLB-FO at a WTP threshold of $38,201/QALY. The gene discussed is ERBB2; the disease is adenocarcinoma.